Global pharma giant Eli Lilly has announced plans to invest more than $6 billion in a cutting-edge manufacturing facility in Huntsville, Alabama, marking one of the largest initial investments in the state’s history that aims at creating hundreds of jobs.

 

The new site will produce next-generation synthetic medicine active pharmaceutical ingredients (APIs), including Lilly’s first oral GLP-1 receptor agonist, orforglipron, which the company expects to submit for global regulatory approval for obesity by year-end.

 

The facility will bring 450 high-value jobs to the area, including engineers, scientists, operations staff, and lab technicians. Construction, slated to begin in 2026, is expected to generate 3,000 additional jobs. Completion is projected for 2032.

 

“Huntsville's track record of science and innovation, supported by advanced manufacturing expertise and a skilled workforce, makes Alabama an ideal location for Lilly to expand domestic manufacturing capacity for next‑generation medicines,” said David A. Ricks, Lilly chair and CEO. 

 

“... investment continues the onshoring of active pharmaceutical ingredient (API) production, strengthening supply chain resilience and reliable access to medicines for patients in the US.”

 

Lilly estimates that every dollar invested in Huntsville could generate up to four dollars in local economic activity. For each manufacturing job created, several more are expected in related sectors, including supply chain, logistics, and retail.

 

“Huntsville and our entire state have a proven legacy of innovation, and there is no better home for Lilly than right here in Alabama. Our roots in the biosciences industry run deep, and Alabama's contributions to this burgeoning sector continue,” said Governor Kay Ivey. 

 

“We are proud to welcome Lilly's new US manufacturing facility, which we are thrilled is the largest initial investment in our state's history. No doubt, Alabamians will help Lilly do things that have never been done before, and we will ensure this great company achieves their mission of improving the health and well-being of people all around the country and globe.”

 

The Greenbrier South site was chosen from more than 300 applicants, partly due to its proximity to the HudsonAlpha Institute for Biotechnology, a major bioscience hub supporting workforce training and research. The region also offers easy access to utilities, transportation, and favorable zoning and incentives.

 

Lilly plans to integrate advanced technologies, including machine learning, AI, digital monitoring systems, and data analytics, to optimize operations and ensure a reliable supply of safe, high-quality medicines.

 

“By establishing this new facility, Lilly is deepening America's expertise in advanced chemical synthesis and setting new standards for sustainable manufacturing,” said Edgardo Hernandez, executive vice president and president of Lilly Manufacturing Operations. 

 

“Our investment not only expands our technical capabilities but also reinforces our commitment to environmental stewardship, leveraging innovative processes to minimize waste and achieve carbon neutrality. Each step forward strengthens our US operations and supports healthier communities for the future.”